Results 61 to 70 of about 252,541 (298)

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression

Advanced Science, EarlyView.
A unique subset of CD9+ B cells regulates germinal center B (GC‐B) cell regression by inducing T follicular helper (Tfh) cell apoptosis through multiple signaling pathways, such as ALCAM‐CD6. FOXP1 plays a key role in GC‐B cell differentiation. These findings clarify mechanisms of GC degeneration and termination and offer potential targets for adenoid ...
Wenjing Liao, Lijuan Song, Meiqian Xu, Tianhao Liang, Yixuan Chen, Gui Chen, Zaihuan Lin, Huakang Du, Guofei Feng, Zhiming Feng, Qi Zhang, Fan Pan, Saixuan Yang, Xinyin Zhang, Wenxu Peng, Tianlong Li, Zhuoshen Lin, Yabang Chen, Jiayi Liu, Baoxin Peng, Yan Liu, Xing Niu, Ting Li, Chengyu Huang, Ke Mo, Jianlei Xie, Yu Zou, Xiaowen Zhang   +27 more
wiley   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Journal of Immunology Research, 2020
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited.
Lichen Zhu, Xiaomei Yang, Dani Zhong, Shenxia Xie, Wei Shi, Yangzi Li, Xiaoqiong Hou, HuaYao, Huihui Zhou, Minlong Zhao, Ziqiang Ding, Xinyue Zhao, Fengzhen Mo, Shihua Yin, Aiqun Liu, Xiaoling Lu   +15 more
doaj   +1 more source

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity

Journal for ImmunoTherapy of Cancer, 2023
Background Hematologic toxicities, including coagulopathy, endothelial activation, and cytopenias, with CD19-targeted chimeric antigen receptor (CAR) T-cell therapies correlate with cytokine release syndrome (CRS) and neurotoxicity severity, but little ...
Hannah Smith, Haneen Shalabi, Bonnie Yates, Nirali N Shah, Hao-Wei Wang, Terry J Fry, Dong Chen, Kevin Parker, Martin Ongkeko, Yanyu Wang, Jennifer Jess, Alina Dulau-Florea, Jon Inglefield, Dan Lichtenstein, Fiorella Schischlik, Shilpa Shahani, Ann Cullinane, Eli Kane, Lauren Little, Ansuman Satpathy, Jay Lozier   +20 more
doaj   +1 more source

Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy

Advanced Science, EarlyView.
By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng, Lei Zheng, Rongkun Tao, Sirui Zheng, Yanke Zhong, Yongxia Niu, Peng Zhang, Xiang Ma, Chen Yang, Min Zhang, Fuyu Duan, Jing Yang, Xuan Wei, Xiang Zhou, Zhenbiao Yang, Zhaoxi Sun, Qizhou Lian   +16 more
wiley   +1 more source

Higher levels of CD19(+) leukocytes in Gaucher disease patients as a potential marker for malignancy

, 2018
Aim: Gaucher disease is an autosomal recessive lysosomal storage disease caused by insufficient glucocerebrosidase activity resulting in accumulation of glucosylceramide, particularly in macrophages. Multiple myeloma and B cell lymphoma are considered to
Canda, Ebru, Kose, Melis, Ucar, Sema Kalkan, Coker, Mahmut, Sagin, Ferhan, Sozmen, Eser Y., Dondurmaci, Meral   +6 more
core   +1 more source

Blood Cell‐Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING‐Amplified Photothermal Immunity for Metastatic Triple‐Negative Breast Cancer Therapy

Advanced Science, EarlyView.
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley   +1 more source

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Pharmaceutics, 2020
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia
Gils Roex, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poiré, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, Sébastien Anguille   +8 more
doaj   +1 more source

PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy

Advanced Science, EarlyView.
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu, Qiang Chen, Zhe Zhou, Yuekang Xu, Jinyao Li   +4 more
wiley   +1 more source